theory clinical_104_3
imports Main


begin

typedecl entity
typedecl event

consts
  HER2 :: "entity ⇒ bool"
  V777L :: "entity ⇒ bool"
  Mutation :: "entity ⇒ bool"
  Located :: "entity ⇒ entity ⇒ bool"
  IntracellularKinaseDomain :: "entity"
  Contribute :: "event ⇒ bool"
  Directly :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  Resistance :: "entity ⇒ bool"
  Trastuzumab :: "entity ⇒ bool"
  Binds :: "entity ⇒ entity ⇒ bool"
  HER2ActivatingMutation :: "entity"
  Related :: "event ⇒ bool"
  InducedBy :: "entity ⇒ entity ⇒ bool"
  RelatedTo :: "event ⇒ entity ⇒ bool"
  Mechanism :: "entity ⇒ bool"
  Identify :: "event ⇒ bool"
  Specific :: "entity ⇒ bool"
  Through :: "event ⇒ entity ⇒ bool"
  Lead :: "event ⇒ bool"
  Treatment :: "entity ⇒ bool"

(* Explanation 1: The HER2 V777L mutation, located in the intracellular kinase domain, may not directly contribute to trastuzumab resistance, as trastuzumab binds to the extracellular kinase domain. *)
axiomatization where
  explanation_1: "∃x y z e. HER2 x ∧ V777L x ∧ Mutation x ∧ Located x IntracellularKinaseDomain ∧ Contribute e ∧ ¬Directly e ∧ Agent e x ∧ Patient e x ∧ Resistance z ∧ Trastuzumab z ∧ Binds z ExtracellularKinaseDomain"

(* Explanation 2: The resistance induced by a HER2-activating mutation may not be directly related to the HER2 V777L mutation. *)
axiomatization where
  explanation_2: "∃x y z e. Resistance x ∧ InducedBy x HER2ActivatingMutation ∧ Related e ∧ ¬Directly e ∧ Agent e x ∧ ¬RelatedTo e HERV777L"

(* Explanation 3: There is a need to identify a specific mechanism through which the HER2 V777L mutation could lead to treatment resistance to trastuzumab. *)
axiomatization where
  explanation_3: "∃x y z e. Mechanism x ∧ Identify e ∧ Specific x ∧ Through e x ∧ Lead e ∧ Agent e HERV777L ∧ Patient e z ∧ Treatment z ∧ Trastuzumab z"


theorem hypothesis:
 assumes asm: "Targeting(x, HERV777L, y, z) ∧ Inhibitor(y) ∧ Irreversible(y) ∧ TyrosineKinase(y) ∧ Overcome(z)"
  (* Hypothesis: Targeting the HER V777L mutation with an irreversible tyrosine kinase inhibitor may overcome treatment resistance. *)
 shows "∃x y z e. Targeting(x, HERV777L, y, z) ∧ Inhibitor(y) ∧ Irreversible(y) ∧ TyrosineKinase(y) ∧ Overcome(e) ∧ Agent e x ∧ Patient e z ∧ Resistance z ∧ Treatment z"
  sledgehammer
  oops

end
